Cargando…

Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”

Detalles Bibliográficos
Autores principales:	van Vollenhoven, Ronald F, Tas, Sander W, Nurmohamed, Michael T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359557/ https://www.ncbi.nlm.nih.gov/pubmed/34389606 http://dx.doi.org/10.1136/annrheumdis-2021-221146

Ejemplares similares

Initial data from the COVID-19 Global Rheumatology Alliance provider registries
por: Vanjak, Anthony
Publicado: (2020)

COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs
por: Tsai, Jih-Jin, et al.
Publicado: (2023)

Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Hahn, Timothy, et al.
Publicado: (2022)

Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries
por: Gianfrancesco, Milena A, et al.
Publicado: (2020)

Correction: Intraarticular steroids as DMARD-sparing agents for juvenile idiopathic arthritis flares: Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Hahn, Timothy, et al.
Publicado: (2022)

Initial data from the COVID-19 Global Rheumatology Alliance provider registries – Authors' reply
por: Gianfrancesco, Milena A
Publicado: (2020)

Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry
por: Jatuworapruk, Kanon, et al.
Publicado: (2022)

The impact of COVID-19 on rheumatology training—results from the COVID-19 Global Rheumatology Alliance trainee survey
por: Young, Kristen, et al.
Publicado: (2022)

Predictors of hospitalization in patients with rheumatic disease and COVID-19 in Ireland: data from the COVID-19 global rheumatology alliance registry
por: Conway, Richard, et al.
Publicado: (2021)

COVID‐19 outcomes among rheumatic disease patients in Kuwait: Data from the COVID‐19 Global Rheumatology Alliance (C19‐GRA) physician registry
por: Abutiban, Fatemah, et al.
Publicado: (2022)

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
por: Strangfeld, Anja, et al.
Publicado: (2021)

Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry
por: Yeoh, Su-Ann, et al.
Publicado: (2022)

Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry
por: Conway, Richard, et al.
Publicado: (2022)

Biological or targeted synthetic DMARDs increase COVID-19 severity
Publicado: (2021)

Baseline Description of the Juvenile Localized Scleroderma Subgroup From the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry
por: Wu, Eveline Y., et al.
Publicado: (2019)

The COVID-19 Global Rheumatology Alliance: collecting data in a pandemic
por: Robinson, Philip C., et al.
Publicado: (2020)

Prescription Trends of Biologic DMARDs in Treating Rheumatologic Diseases: Changes of Medication Availability in COVID-19
por: Radić, Mislav, et al.
Publicado: (2023)

Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
por: Sattui, Sebastian E, et al.
Publicado: (2021)

Familial autoimmunity in the childhood arthritis and rheumatology research alliance registry
por: Prahalad, Sampath, et al.
Publicado: (2016)

Baseline characteristics of children with juvenile dermatomyositis enrolled in the first year of the new Childhood Arthritis and Rheumatology Research Alliance registry
por: Neely, Jessica, et al.
Publicado: (2022)

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope
por: Zhao, Sizheng Steven, et al.
Publicado: (2023)

COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey
por: Putman, Michael, et al.
Publicado: (2022)

076 Risk of severe COVID-19 associated with immune-modifying drugs: data from PsoProtect and Global Rheumatology Alliance registries
por: Group, P Study, et al.
Publicado: (2022)

Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry
por: Kihara, Mari, et al.
Publicado: (2022)

Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries
por: Machado, Pedro M, et al.
Publicado: (2023)

Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry
por: Olsen, Inge C, et al.
Publicado: (2019)

Predictors of drug survival for biologic and targeted synthetic DMARDs in rheumatoid arthritis: Analysis from the TRA Clinical Electronic Registry
por: Lin, Ching-Tsai, et al.
Publicado: (2021)

Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry
por: Jung, Ju-Yang, et al.
Publicado: (2023)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

Does COVID-19 cause an increased risk of hospitalization or death in patients with inflammatory rheumatic diseases treated with biological DMARDs or targeted synthetic DMARDs?
por: Lwin, May, et al.
Publicado: (2020)

The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
por: Roberts, Lynden, et al.
Publicado: (2017)

Development of a Prediction Model for COVID‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry
por: Izadi, Zara, et al.
Publicado: (2022)

Biologic DMARDs and targeted synthetic DMARDs and the risk of all-cause mortality in rheumatoid arthritis: A systematic review and meta-analysis
por: Pang, Mengduan, et al.
Publicado: (2022)

SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry
por: Liew, Jean, et al.
Publicado: (2022)

HBV and targeted synthetic (ts)DMARDs: what have we learned from bDMARDs and tsDMARDs?
por: Gremese, Elisa, et al.
Publicado: (2020)

Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Henderson, Lauren A., et al.
Publicado: (2016)

Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
por: Beukelman, Timothy, et al.
Publicado: (2021)

Prediagnosis radiological progression in rheumatoid arthritis: a novel tool to study the effects of early DMARD therapy
por: Wick, MC, et al.
Publicado: (2004)

To stop the erosion of hope: the DMARD category and the place of semantics in modern rheumatology
por: Buer, Jonas Kure
Publicado: (2017)

Saudi cultural adaptation of the “compliance questionnaire of Rheumatology” for Rheumatoid arthritis patients on disease modifying anti-rheumatic drugs (DMARDs)
por: Aljohani, Roaa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j5f5rej7dn7tpsbheilc9v3ml8